Neurobiology of Aging
Volume 30, Issue 6 , Pages 847-863 , June 2009

Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin

  • David F. Fischer

      Affiliations

    • Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Present address: BioFocus DPI, a Galapagos Company, PO Box 127, 2300 CA Leiden, The Netherlands. Tel.: +31 71 7506 728; fax: +31 71 7506 701.
    • These authors contributed equally.
    • ,
  • Renske van Dijk

      Affiliations

    • Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
    • These authors contributed equally.
    • ,
  • Paula van Tijn

      Affiliations

    • Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
    • These authors contributed equally.
    • Present address: Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences & University Medical Centre Utrecht, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands.
    • ,
  • Barbara Hobo

      Affiliations

    • Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
    • ,
  • Marian C. Verhage

      Affiliations

    • Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
    • ,
  • Roel C. van der Schors

      Affiliations

    • Department of Molecular and Cellular Neurobiology, Research Institute Neurosciences, Faculty of Earth and Life Sciences, Vrije Universiteit, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
    • ,
  • Ka Wan Li

      Affiliations

    • Department of Molecular and Cellular Neurobiology, Research Institute Neurosciences, Faculty of Earth and Life Sciences, Vrije Universiteit, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
    • ,
  • Jan van Minnen

      Affiliations

    • Department of Molecular and Cellular Neurobiology, Research Institute Neurosciences, Faculty of Earth and Life Sciences, Vrije Universiteit, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
    • ,
  • Elly M. Hol

      Affiliations

    • Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
    • ,
  • Fred W. van Leeuwen

      Affiliations

    • Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
    • Maastricht University, Department of Neuroscience, Faculty of Health, Medicine and Life Sciences, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author at: Maastricht University, Department of Neuroscience, Faculty of Health, Medicine and Life Sciences, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands. Tel.: +31 43 3881044; fax: +31 43 367 1096.

Received 6 March 2008 ,Revised 28 May 2008 ,Accepted 18 June 2008.

References 

  1. Almeida CG, Takahashi RH, Gouras GK. β-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin–proteasome system. J. Neurosci. 2006;26(16):4277–4288
  2. Barondes SH, Cohen HD. Delayed and sustained effect of acetoxycycloheximide on memory in mice. Proc. Natl. Acad. Sci. U.S.A. 1967;58(1):157–164
  3. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin–proteasome system by protein aggregation. Science. 2001;292(5521):1552–1555
  4. Bennett EJ, Bence NF, Jayakumar R, Kopito RR. Global impairment of the ubiquitin–proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell. 2005;17(3):351–365
  5. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, et al. Global changes to the ubiquitin system in Huntington's disease. Nature. 2007;448(7154):704–708
  6. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 2005;115(6):1449–1457
  7. Bi X, Yong AP, Zhou J, Ribak CE, Lynch G. Rapid induction of intraneuronal neurofibrillary tangles in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2001;98(15):8832–8837
  8. Braak H, Tredici KD, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 2003;24(2):197–211
  9. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal. Biochem. 1976;72:248–254
  10. Caroni P. Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J. Neurosci. Methods. 1997;71:3–9
  11. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I. Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol. Med. 2002;33(4):562–571
  12. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II. Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 2002;82(6):1524–1532
  13. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 2003;85(6):1394–1401
  14. Choi J, Forster MJ, McDonald SR, Weintraub ST, Carroll CA, Gracy RW. Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimer's disease. Free Radic Biol. Med. 2004;36(9):1155–1162
  15. Choi T, Huang M, Gorman C, Jaenisch R. A generic intron increases gene expression in transgenic mice. Mol. Cell. Biol. 1991;11(6):3070–3074
  16. Christie G, Markwell RE, Gray CW, Smith L, Godfrey F, Mansfield F, et al. Alzheimer's disease: correlation of the suppression of β-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome. J. Neurochem. 1999;73(1):195–204
  17. Ciechanover A, Brundin P. The ubiquitin–proteasome system in neurodegenerative diseases. Sometimes the chicken, sometimes the egg. Neuron. 2003;40(2):427–446
  18. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl). 1997;132(2):107–124
  19. Dahlmann B, Ruppert T, Kuehn L, Merforth S, Kloetzel PM. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J. Mol. Biol. 2000;303(5):643–653
  20. David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, et al. β-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics. 2006;6(24):6566–6577
  21. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. J. Neurochem. 2002;83(1):176–185
  22. Day IN, Thompson RJ. Levels of immunoreactive aldolase C, creatine kinase-BB, neuronal and non-neuronal enolase, and 14-3-3 protein in circulating human blood cells. Clin. Chim. Acta. 1984;136(2–3):219–228
  23. De Pril R, Fischer DF, Maat-Schieman ML, Hobo B, De Vos RA, Brunt ER, et al. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum. Mol. Genet. 2004;13(16):1803–1813
  24. de Vrij FMS, Fischer DF, van Leeuwen FW, Hol EM. Protein quality control in Alzheimer's disease by the ubiquitin–proteasome system. Prog. Neurobiol. 2004;74(5):249–270
  25. de Vrij FMS, Sluijs JA, Gregori L, Fischer DF, Hermens WT, Goldgaber D, et al. Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death. FASEB J. 2001;15(14):2680–2688
  26. Ding Q, Bruce-Keller AJ, Chen Q, Keller JN. Analysis of gene expression in neural cells subject to chronic proteasome inhibition. Free Radic Biol. Med. 2004;36(4):445–455
  27. Ding Q, Dimayuga E, Martin S, Bruce-Keller AJ, Nukala V, Cuervo AM, et al. Characterization of chronic low-level proteasome inhibition on neural homeostasis. J. Neurochem. 2003;86(2):489–497
  28. Doll D, Sarikas A, Krajcik R, Zolk O. Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. Biochem. Biophys. Res. Commun. 2007;353(2):436–442
  29. Drews O, Wildgruber R, Zong C, Sukop U, Nissum M, Weber G, et al. Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol. Cell Proteomics. 2007;6(11):2021–2031
  30. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28(1):41–51
  31. Fischer DF, De Vos RA, Van Dijk R, De Vrij FM, Proper EA, Sonnemans MA, et al. Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J. 2003;17(14):2014–2024
  32. Flexner JB, Flexner LB, Stellar E. Memory in mice as affected by intracerebral puromycin. Science. 1963;141:57–59
  33. Fonseca R, Vabulas RM, Hartl FU, Bonhoeffer T, Nagerl UV. A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP. Neuron. 2006;52(2):239–245
  34. Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, Haas C, et al. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp. Neurol. 2005;192(2):274–287
  35. Fratta P, Engel WK, Van Leeuwen FW, Hol EM, Vattemi G, Askanas V. Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers. Neurology. 2004;63(6):1114–1117
  36. Gaczynska M, Rock KL, Spies T, Goldberg AL. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc. Natl. Acad. Sci. U.S.A. 1994;91(20):9213–9217
  37. Gerez L, de Haan A, Hol EM, Fischer DF, van Leeuwen FW, van Steeg H, et al. Molecular misreading: the frequency of dinucleotide deletions in neuronal mRNAs for β-amyloid precursor protein and ubiquitin B. Neurobiol. Aging. 2005;26(2):145–155
  38. Gilchrist CA, Gray DA, Stieber A, Gonatas NK, Kopito RR. Effect of ubiquitin expression on neuropathogenesis in a mouse model of familial amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 2005;31(1):20–33
  39. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, et al. Ubiquitin hydrolase Uch-L1 rescues β-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006;126(4):775–788
  40. Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D. Amyloid β-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 1995;270(34):19702–19708
  41. Gregori L, Hainfeld JF, Simon MN, Goldgaber D. Binding of amyloid β protein to the 20S proteasome. J. Biol. Chem. 1997;272(1):58–62
  42. Grune T, Merker K, Sandig G, Davies KJ. Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem. Biophys. Res. Commun. 2003;305(3):709–718
  43. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356
  44. Hendil KB, Kristensen P, Uerkvitz W. Human proteasomes analysed with monoclonal antibodies. Biochem. J. 1995;305(Pt 1):245–252
  45. Hol EM, Fischer DF, Ovaa H, Scheper W. Ubiquitin–proteasome system as a pharmacological target in neurodegeneration. Expert. Rev. Neurother. 2006;6(9):1337–1347
  46. Hol EM, Van Dijk R, Gerez L, Sluijs JA, Hobo B, Tonk MT, et al. Frameshifted β-amyloid precursor protein (APP+1) is a secretory protein, and the level of APP+1 in cerebrospinal fluid is linked to Alzheimer pathology. J. Biol. Chem. 2003;278(41):39637–39643
  47. Hol EM, van Leeuwen FW, Fischer DF. The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B(+1). Trends Mol. Med. 2005;11(11):488–495
  48. Hope AD, de Silva R, Fischer DF, Hol EM, van Leeuwen FW, Lees AJ. Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression. J. Neurochem. 2003;86(2):394–404
  49. Hope AD, Lashley T, Lees AJ, De Silva R. Failure in heat-shock protein expression in response to UBB(+1) protein in progressive supranuclear palsy in humans. Neurosci. Lett. 2004;359(1–2):94–98
  50. Hsiao-Ashe K. Learning and memory in transgenic mice modeling Alzheimer's disease. Learn. Memory. 2001;8(6):301–308
  51. Hyun DH, Lee MH, Halliwell B, Jenner P. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?. J. Neurochem. 2002;83(2):360–370
  52. Jin BF, He K, Wang HX, Wang J, Zhou T, Lan Y, et al. Proteomic analysis of ubiquitin–proteasome effects: insight into the function of eukaryotic initiation factor 5A. Oncogene. 2003;22(31):4819–4830
  53. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 2003;85(1):115–122
  54. Kelleher RJ, Govindarajan A, Tonegawa S. Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron. 2004;44(1):59–73
  55. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 2000;75(1):436–439
  56. Kim SH, Fountoulakis M, Cairns NJ, Lubec G. Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochem. Biophys. Res. Commun. 2002;296(4):970–975
  57. Komatsu M, Waguri S, Chiba T, Murata S, Iwata JI, Tanida I, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441(7095):880–884
  58. Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol. Cell. 2007;26(2):175–188
  59. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, et al. Inhibition of the ubiquitin–proteasome system in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2000;97(18):9902–9906
  60. Lee PD, Sladek R, Greenwood CM, Hudson TJ. Control genes and variability: absence of ubiquitous reference transcripts in diverse Mammalian expression studies. Genome Res. 2002;12(2):292–297
  61. Li KW, Hornshaw MP, Van Der Schors RC, Watson R, Tate S, Casetta B, et al. Proteomics analysis of rat brain postsynaptic density: implications of the diverse protein functional groups for the integration of synaptic physiology. J. Biol. Chem. 2004;279(2):987–1002
  62. Lindsten K, De Vrij FM, Verhoef LG, Fischer DF, Van Leeuwen FW, Hol EM, et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell. Biol. 2002;157(3):417–427
  63. Maren S. Neurobiology of pavlovian fear conditioning. Annu. Rev. Neurosci. 2001;24(1):897–931
  64. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274(5293):1678–1683
  65. McPhaul LW, Wang J, Hol EM, Sonnemans MA, Riley N, Nguyen V, et al. Molecular misreading of the ubiquitin B gene and hepatic mallory body formation. Gastroenterology. 2002;122(7):1878–1885
  66. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U.S.A. 1999;96(18):10403–10408
  67. Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science. 1987;235(4796):1641–1644
  68. Nagle GT, de Jong-Brink M, Painter SD, Li KW. Structure, localization and potential role of a novel molluscan trypsin inhibitor in Lymnaea. Eur. J. Biochem. 2001;268(5):1213–1221
  69. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab. Anim. 2002;36(1):20–42
  70. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43(3):321–332
  71. Oh S, Hong HS, Hwang E, Sim HJ, Lee W, Shin SJ, et al. Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech. Ageing Dev. 2005;126(12):1292–1299
  72. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, Uchida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J. Biol. Chem. 1999;274(34):23787–23793
  73. Periquet M, Corti O, Jacquier S, Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J. Neurochem. 2005;95:1259–1276
  74. Pickart CM. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001;70:503–533
  75. Ponelies N, Hirsch T, Krehmeier U, Denz C, Patel MB, Majetschak M. Cytosolic ubiquitin and ubiquitylation rates in human peripheral blood mononuclear cells during sepsis. Shock. 2005;24(1):20–25
  76. Puttaparthi K, Wojcik C, Rajendran B, DeMartino GN, Elliott JL. Aggregate formation in the spinal cord of mutant SOD1 transgenic mice is reversible and mediated by proteasomes. J. Neurochem. 2003;87(4):851–860
  77. Routtenberg A, Rekart JL. Post-translational protein modification as the substrate for long-lasting memory. Trends Neurosci. 2005;28(1):12–19
  78. Salehi A, Swaab DF. Diminished neuronal metabolic activity in Alzheimer's disease. J. Neural Transm. 1999;106(9/10):955–986
  79. Schonberger SJ, Edgar PF, Kydd R, Faull RL, Cooper GJ. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics. 2001;1(12):1519–1528
  80. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298(5594):789–791
  81. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6(4):487–498
  82. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996;68(5):850–858
  83. Shin SJ, Lee SE, Boo JH, Kim M, Yoon YD, Kim SI, et al. Profiling proteins related to amyloid deposited brain of Tg2576 mice. Proteomics. 2004;4(11):3359–3368
  84. Shringarpure R, Grune T, Mehlhase J, Davies KJ. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J. Biol. Chem. 2003;278(1):311–318
  85. Silva AJ, Simpson EM, Takahashi JS, Lipp H-P, Nakanishi S, Wehner JM, et al. Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice. Neuron. 1997;19(4):755–759
  86. Song S, Jung YK. Alzheimer's disease meets the ubiquitin–proteasome system. Trends Mol. Med. 2004;10(11):565–570
  87. Song S, Kim SY, Hong YM, Jo DG, Lee JY, Shim SM, et al. Essential role of E2-25K/Hip-2 in mediating amyloid-β neurotoxicity. Mol. Cell. 2003;12(3):553–563
  88. Sternberger LA, Hardy PH, Cuculis JJ, Meyer HG. The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen–antibody complex (horseradish peroxidase–antihorseradish peroxidase) and its use in identification of spirochetes. J. Histochem. Cytochem. 1970;18(5):315–333
  89. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, et al. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis. 2007;11(2):153–164
  90. Swaab DF. Brain aging and Alzheimer's disease, “wear and tear” versus “use it or lose it”. Neurobiol. Aging. 1991;12(4):317–324
  91. Takada K, Hibi N, Tsukada Y, Shibasaki T, Ohkawa K. Ability of ubiquitin radioimmunoassay to discriminate between monoubiquitin and multi-ubiquitin chains. Biochim. Biophys. Acta. 1996;1290(3):282–288
  92. Tilleman K, Stevens I, Spittaels K, Haute CV, Clerens S, Van Den Bergh G, et al. Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view. Proteomics. 2002;2(1):94–104
  93. Tilleman K, Van Den Haute C, Geerts H, Leuven Fv F, Esmans EL, Moens L. Proteomics analysis of the neurodegeneration in the brain of tau transgenic mice. Proteomics. 2002;2(6):656–665
  94. Tsugita A, Kawakami T, Uchida T, Sakai T, Kamo M, Matsui T, et al. Proteome analysis of mouse brain: two-dimensional electrophoresis profiles of tissue proteins during the course of aging. Electrophoresis. 2000;21(9):1853–1871
  95. Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S. Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem. Res. 2002;27(10):1245–1253
  96. van Leeuwen FW, de Kleijn DPV, van den Hurk HH, Neubauer A, Sonnemans MAF, Sluijs JA, et al. Frameshift mutants of b amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science. 1998;279:242–247
  97. van Leeuwen FW, van Tijn P, Sonnemans MA, Hobo B, Mann DM, Van Broeckhoven C, et al. Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. Neurology. 2006;66(2 Suppl. 1):S86–S92
  98. van Leuven F. Single and multiple transgenic mice as models for Alzheimer's disease. Prog. Neurobiol. 2000;61(3):305–312
  99. van Tijn P, de Vrij FM, Schuurman KG, Dantuma NP, Fischer DF, van Leeuwen FW, et al. Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease. J. Cell Sci. 2007;120:1615–1623
  100. van Tijn P, Hol EM, van Leeuwen FW, Fischer DF. The neuronal ubiquitin–proteasome system: murine models and their neurological phenotype. Prog. Neurobiol. 2008;85(2):176–193
  101. Wang Q, Woltjer RL, Cimino PJ, Pan C, Montine KS, Zhang J, et al. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J. 2005;19(7):869–871
  102. Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M. Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. Physiol. Genomics. 2000;2:143–147
  103. Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 2002;5(7):633–639

PII: S0197-4580(08)00216-9

doi: 10.1016/j.neurobiolaging.2008.06.009

Neurobiology of Aging
Volume 30, Issue 6 , Pages 847-863 , June 2009

Article Tools

* Image Usage & Resolution